8月22日,国家药监局正式批准注射用德达博妥单抗(中文商品名:达卓优)新适应症,用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、(HER2)阴性乳腺癌成人患者。 此次获批是基于TROPION-Breast01全球Ⅲ期研究的积极结果。在TROPION-Breast01研究中,对中国83名患者进行的事后分析显示,接受德达博妥单抗治疗的患者中位无...
Source Link8月22日,国家药监局正式批准注射用德达博妥单抗(中文商品名:达卓优)新适应症,用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、(HER2)阴性乳腺癌成人患者。 此次获批是基于TROPION-Breast01全球Ⅲ期研究的积极结果。在TROPION-Breast01研究中,对中国83名患者进行的事后分析显示,接受德达博妥单抗治疗的患者中位无...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.